Greenwich LifeSciences, Inc. (GLSI)

9.69 +0.05 (+0.52%) At close: 04:00PM EDT

Greenwich LifeSciences, Inc.

Building 14
3992 Bluebonnet Drive
Stafford, TX 77477
United States
832 819 3232
https://greenwichlifesciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Snehal S. Patel	CEO, CFO & Director	507.48k	N/A	1964
Mr. Eric Rothe	Founder & Independent Director	N/A	N/A	1976
Dr. Frank Joseph Daugherty M.D.	Chief Medical Officer & Director	N/A	N/A	1951

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Corporate Governance

Greenwich LifeSciences, Inc.’s ISS Governance QualityScore as of February 1, 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.